Study: Omicron evades some but not all monoclonal antibodies
Por um escritor misterioso
Descrição
Several, but not all, of the human monoclonal antibodies used clinically to prevent patients from becoming severely ill from COVID-19 may not be protective against the omicron variant now sweeping across the United States, researchers reported Jan. 19 in the journal Nature Medicine.
Advances in the Omicron variant development - Vitiello - 2022 - Journal of Internal Medicine - Wiley Online Library
Sub-optimal neutralisation of omicron (B.1.1.529) variant by antibodies induced by vaccine alone or SARS-CoV-2 Infection plus vaccine (hybrid immunity) post 6-months - eBioMedicine
Even if SARS-CoV-2 Omicron evades antibodies, immunity still exists
SARS‑CoV‑2 Omicron variant escapes monoclonal antibodies
Interaction Analysis of the Spike Protein of Delta and Omicron Variants of SARS-CoV-2 with hACE2 and Eight Monoclonal Antibodies Using the Fragment Molecular Orbital Method
Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies - eBioMedicine
New study suggests most monoclonal antibody treatments are ineffective against Omicron SARS-CoV-2 variant
Monoclonal antibodies lock down SARS-CoV-2 spike: Trends in Immunology
SARS-CoV-2 Study Forecasts Emergence of Immune Escape Variants
Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers
An Update on Omicron Subvariants, Johns Hopkins
Neutralization Escape by SARS-CoV-2 Omicron Subvariant BA.4.6
BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection
Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles
de
por adulto (o preço varia de acordo com o tamanho do grupo)
